Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 562,801
  • Shares Outstanding, K 155,470
  • Annual Sales, $ 3,960 K
  • Annual Income, $ -130,090 K
  • 60-Month Beta 2.14
  • Price/Sales 148.09
  • Price/Cash Flow N/A
  • Price/Book 1.90
Trade ADAP with:

Options Overview

Details
  • Implied Volatility 95.85%
  • Historical Volatility 42.36%
  • IV Percentile 10%
  • IV Rank 19.05%
  • IV High 184.65% on 10/22/20
  • IV Low 74.96% on 07/16/21
  • Put/Call Vol Ratio 0.12
  • Today's Volume 174
  • Volume Avg (30-Day) 239
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 9,481
  • Open Int (30-Day) 9,306

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.25
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -4.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +1.97%
on 07/19/21
4.45 -18.65%
on 06/29/21
-0.54 (-12.98%)
since 06/23/21
3-Month
3.55 +1.97%
on 07/19/21
5.97 -39.36%
on 04/30/21
-1.81 (-33.33%)
since 04/23/21
52-Week
3.55 +1.97%
on 07/19/21
10.93 -66.88%
on 09/17/20
-5.69 (-61.12%)
since 07/23/20

Most Recent Stories

More News
TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2021-2030

Reportlinker.com announces the release of the report "TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2021-2030" - https://www.reportlinker.com/p06103095/?utm_source=GNW...

ADAP : 3.62 (-3.98%)
GSK : 39.51 (+0.71%)
Thinking about buying stock in Oncternal Therapeutics, Polarityte, Adaptimmune Therapeutics, Oncolytics Biotech, or Precipio?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCT, PTE, ADAP, ONCY, and PRPO.

ADAP : 3.62 (-3.98%)
ONCT : 3.95 (-8.14%)
ONCY : 2.51 (-1.18%)
PTE : 0.79 (unch)
PRPO : 3.02 (-2.27%)
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 Trial

- Data will support BLA filing for afamitresgene autoleucel next year -

ADAP : 3.62 (-3.98%)
First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells -

ADAP : 3.62 (-3.98%)
Adaptimmune Reports First Quarter Financial Results and Business Update

- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO -

ADAP : 3.62 (-3.98%)
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with...

ADAP : 3.62 (-3.98%)
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the...

ADAP : 3.62 (-3.98%)
Thinking about buying stock in Oramed Pharmaceuticals, Mogo, Chiasma, Adaptimmune Therapeutics, or Dynatronics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORMP, MOGO, CHMA, ADAP, and DYNT.

ADAP : 3.62 (-3.98%)
CHMA : 4.24 (-1.62%)
DYNT : 1.29 (+9.32%)
MOGO : 5.70 (-2.73%)
ORMP : 14.40 (+10.26%)
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

- Outlined strategy to build integrated cell therapy company and the Company's "2-2-5-2" five-year core value drivers -

ADAP : 3.62 (-3.98%)
Adaptimmune Therapeutics Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Adaptimmune Therapeutics Plc (NASDAQ:ADAP) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25,...

ADAP : 3.62 (-3.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 4.13
2nd Resistance Point 4.03
1st Resistance Point 3.82
Last Price 3.62
1st Support Level 3.51
2nd Support Level 3.41
3rd Support Level 3.20

See More

52-Week High 10.93
Fibonacci 61.8% 8.11
Fibonacci 50% 7.24
Fibonacci 38.2% 6.37
Last Price 3.62
52-Week Low 3.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar